• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Celcuity Inc (NQ: CELC )

    12.46 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Celcuity Inc

    < Previous 1 2 3 4 Next >
    Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
    Via ACCESSWIRE
    Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Celcuity Closes $100 Million Private Placement
    Via ACCESSWIRE
    Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
    Via ACCESSWIRE
    Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
    Via ACCESSWIRE
    Celcuity: Q2 Earnings Insights
      Celcuity (NASDAQ:CELC) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Earnings Scheduled For May 16, 2022
    Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
    Via Benzinga
    Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
    Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
    Via ACCESSWIRE
    Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
    Via ACCESSWIRE
    Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
    Via ACCESSWIRE
    Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
    Via ACCESSWIRE
    Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
    Via ACCESSWIRE
    Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
    Via ACCESSWIRE
    Earnings Outlook For Celcuity
      Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. Analysts estimate that Celcuity will... 
    Via Benzinga
    Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
    Via ACCESSWIRE
    Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
    Via ACCESSWIRE
    The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million. 
    Via Benzinga
    Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
    MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today... 
    From Celcuity Inc.
    Via AccessWire
    Exposures Product Safety
    Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
    MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
    From Celcuity Inc.
    Via AccessWire
    Recap: Celcuity Q1 Earnings
    Celcuity (NASDAQ:CELC) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Celcuity beat estimated earnings by... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    On Tuesday, 123 stocks made new 52-week lows. 
    Via Benzinga
    Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
    - Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast... 
    From Celcuity Inc.
    Via AccessWire
    Exposures Product Safety
    The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
    Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
    Via Benzinga
    Celcuity Inc. Announces $100 Million Private Placement
    Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a... 
    From Celcuity Inc.
    Via AccessWire
    Earnings Preview For Celcuity
    Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Celcuity will report... 
    Via Benzinga
    Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
    MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
    From Celcuity Inc.
    Via AccessWire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.